ST3GAL2 and ovarian cancer: Furthermore, we have shown that the expression level of ST3GAL2, the enzyme catalyzing SSEA4 synthesis, can be used as a marker to predict clinical outcome of breast and ovarian cancer patients, in particular those treated with chemotherapy.